N-(2-(2,2,6,6-tetramethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl)aniline | 1313603-21-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-(2,2,6,6-tetramethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl)aniline
• 英文别名: N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline；Icmt-IN-7；N-[2-(2,2,6,6-tetramethyl-4-phenyloxan-4-yl)ethyl]aniline
• CAS: 1313603-21-2
• 化学式: C₂₃H₃₁NO
• 分子量: 337.505
• InChiKey: ZLFMQBZRZIATAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,2,6,6-四甲基-2H-3,5,6-三氢吡喃-4-酮 在 哌啶 、 tris-(dibenzylideneacetone)dipalladium(0) 、 lithium aluminium tetrahydride 、 copper(I) bromide dimethylsulfide complex 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 溶剂黄146 、 potassium hydroxide 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 乙醚 、 甲苯 为溶剂， 反应 26.83h， 生成 N-(2-(2,2,6,6-tetramethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl)aniline
  参考文献：
  名称：

  이소프레닐시스테인카복실메틸트랜스퍼라제 저해제를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물

  摘要：

  本发明涉及一种抑制异戊酰丝氨酸羧甲基转移酶(ICMT_Ph)的抑制剂，以及含有其作为有效成分的用于预防或治疗炎症性疾病的组合物。根据本发明，ICMT_Ph已被确认可以抑制前列腺素E2（PGE）和肿瘤坏死因子-α（TNF-α）的产生，因此可以作为对预防或治疗炎症性疾病有用的药物和保健食品使用。

  公开号：

  KR20170088140A

文献信息

• 이소프레닐시스테인카복실메틸트랜스퍼라제 저해제를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
  申请人：Research ＆ Business Foundation SUNGKYUNKWAN UNIVERSITY 성균관대학교산학협력단(220050013604) BRN ▼101-82-12009

  公开号：KR20170088140A

  公开（公告）日：2017-08-01

  본 발명은 이소프레닐시스테인카복실메틸트랜스퍼라제 저해제(ICMT_Ph), 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 ICMT_Ph는, 프로스타글란딘(prostaglandin E2: PGE) 및 종양사멸인자-알파(Tumor Necrosis Factor-α: TNF-α)의 생성을 억제한다는 것이 확인되어, 염증성 질환의 예방 또는 치료에 유용한 의약품 및 건강기능식품으로 사용될 수 있다.

  本发明涉及一种抑制异戊酰丝氨酸羧甲基转移酶(ICMT_Ph)的抑制剂，以及含有其作为有效成分的用于预防或治疗炎症性疾病的组合物。根据本发明，ICMT_Ph已被确认可以抑制前列腺素E2（PGE）和肿瘤坏死因子-α（TNF-α）的产生，因此可以作为对预防或治疗炎症性疾病有用的药物和保健食品使用。
• Discovery and SAR of Methylated Tetrahydropyranyl Derivatives as Inhibitors of Isoprenylcysteine Carboxyl Methyltransferase (ICMT)
  作者：Weston R. Judd、Paul M. Slattum、Khanh C. Hoang、Leena Bhoite、Liisa Valppu、Glen Alberts、Brita Brown、Bruce Roth、Kirill Ostanin、Liwen Huang、Daniel Wettstein、Burt Richards、J. Adam Willardsen

  DOI：10.1021/jm200249a

  日期：2011.7.28

  A series of tetrahydropyranyl (THP) derivatives has been developed as potent inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT) for use as anticancer agents. Structural modification of the submicromolar hit compound 3 led to the potent 3-methoxy substituted analogue 27. Further SAR development around the THP ring resulted in an additional 10-fold increase in potency, exemplified by analogue 75 with an IC50 of 1.3 nM. Active and potent compounds demonstrated a dose-dependent increase in Ras cytosolic protein. Potent ICMT inhibitors also reduced cell viability in several cancer cell lines with growth inhibition (GI(50)) values ranging from 0.3 to >100 mu M. However, none of the cellular effects observed using ICMT inhibitors were as pronounced as those resulting from a farnesyltransferase inhibitor.